Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Non-Current Liabilities (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Total Non-Current Liabilities for 16 consecutive years, with $336.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 22.6% to $336.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $336.9 million, a 22.6% increase, with the full-year FY2025 number at $336.9 million, up 22.6% from a year prior.
  • Total Non-Current Liabilities was $336.9 million for Q4 2025 at Myriad Genetics, down from $353.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $444.1 million in Q2 2021 to a low of -$775.1 million in Q2 2024.
  • A 5-year average of $276.5 million and a median of $315.2 million in 2023 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: crashed 275.92% in 2024, then surged 137.07% in 2025.
  • Myriad Genetics' Total Non-Current Liabilities stood at $320.8 million in 2021, then fell by 16.15% to $269.0 million in 2022, then grew by 17.17% to $315.2 million in 2023, then dropped by 12.82% to $274.8 million in 2024, then rose by 22.6% to $336.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Total Non-Current Liabilities are $336.9 million (Q4 2025), $353.6 million (Q3 2025), and $287.3 million (Q2 2025).